GET DAILY SIGNALSTonix Pharmaceuticals (TNXP): Weighing the Path to $24 After a -76% Slide
Key Takeaways
- The $24 central target is the arithmetic mean of four current, individually verified analyst price targets, rounded from a calculated average of $23.50.
- At a recent price near $4.11, reaching $24 would require upside of roughly 480%, a very large move.
- The current target range is unusually wide, from a low of $14 (Raymond James) to a high of $40 (Alliance Global Partners), reflecting sharp disagreement over the commercial trajectory.
- The strongest supporting factors are growing TONMYA sales, expanding payer coverage, and an advancing clinical pipeline.
- The biggest risks are accelerating cash burn, likely dilution, a generic patent challenge, and a still-unprofitable business model.
- Readers can find additional detail on Major News, Today's Price Move, the Forecast, and Earnings pages for this ticker.
- Explore Trending AI Robots to see AI-driven trading strategies monitoring stocks like this one.
Analyst Price Targets and Consensus View
The $24 figure is not an official published consensus; it is a calculated average of four recent, clearly dated targets. These are: Canaccord Genuity at $18 (Buy, November 10, 2026), Alliance Global Partners at $40 (Buy, lowered from $65 on November 9, 2026), Raymond James at $14 (Strong Buy, lowered from $26 on November 9, 2026), and TD Cowen at $22 (Buy, October 21, 2026).
The mean of these four is $23.50, which rounds to a $24 central target, with a low-to-high range of $14 to $40. Every current rating is a Buy or Strong Buy, yet the spread is enormous, because analysts disagree about how fast TONMYA sales will compound and how much additional equity financing will be needed. Raymond James, for example, cited rising expenses and financing needs alongside constructive TONMYA momentum when cutting its target. This wide dispersion means the average should be read as a broad directional signal, not a precise destination. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Current Market Position and Path Toward the Target
With shares near $4.11, a move to $24 requires about 480% upside, which is a very large move by any standard. The stock trades well below its 52-week high near $20.56 and just above its recent low near $4.00, after a steep post-earnings decline.
Fundamentally, the path would need TONMYA, the company's fibromyalgia treatment, to keep compounding sales while losses narrow meaningfully. In the third quarter of 2026, TONMYA net sales reached roughly $15 million, up 37% sequentially, and total revenue grew to about $17.2 million from $3.3 million a year earlier. Still, the net loss widened, and the company reported a GAAP loss per share near $2.89. For the shares to multiply several-fold, investors would likely need to see durable revenue growth, a credible path to profitability, and successful pipeline readouts.
What Could Support a Move Toward the Target
The bull case rests on commercial execution and optionality. Covered lives have expanded to roughly 53% of the U.S. population, aided by managed Medicare agreements and near-nationwide Medicaid access. A sales-force expansion in September 2026 lifted reach toward about 70% of target prescribers. Beyond TONMYA, the pipeline includes TNX-102 SL for major depressive disorder, a Phase 2 Lyme disease antibody (TNX-4800) expected to start in early 2027, and an investigator-initiated kidney-transplant study. Meaningful clinical or partnering news could support a re-rating.
What Could Prevent the Target From Being Reached
The obstacles are substantial. Cash fell to roughly $163 million at the end of the third quarter, and nine-month operating cash burn more than doubled year over year, pointing to further dilution. Dr. Reddy's Laboratories filed a Paragraph IV patent challenge against TONMYA, creating uncertainty over long-term exclusivity even though core patents extend to 2034. Growth has also decelerated sharply from earlier quarters, and the company remains deeply unprofitable. Any setback in financing, launch momentum, or the pipeline could keep shares depressed.
Technical Levels and Market Structure
The stock is in a pronounced long-term downtrend, down about 76% over the past year. The $4.00 area, near the recent 52-week low, is the most important nearby support level; a decisive break below it would mark fresh lows. On the upside, prior breakdown zones near $5 and the psychological $10 level would act as resistance well before any approach to the $24 target. The wide analyst range of $14 to $40 itself reflects the unusually high uncertainty embedded in the chart and the story. From what I see, monitoring these levels with systematic tools helps clarify the setup.
Time Horizon and What Investors Should Monitor
Analyst price targets generally reflect a research horizon of about 12 months, though specific horizons vary by firm and are not always disclosed. Investors should watch quarterly TONMYA prescription and revenue trends, cash balance and any financing announcements, progress on the Paragraph IV litigation, and the Q1 2027 starts of the TNX-4800 and TNX-1500 studies. Analyst revisions after each earnings report will also matter, given how quickly targets have been cut recently. I’m watching this closely as the next catalysts approach.
Using Tickeron’s AI Daily Buy/Sell Signals for Monitoring
In my view, Tickeron’s AI Daily Buy/Sell Signals provide a practical way to track volatile names like this. The tool applies artificial intelligence to scan market conditions and technical behavior across thousands of stocks, delivering Buy, Sell, or Hold signals that can highlight shifts more efficiently than manual checks alone. I find it useful for spotting inflection points in real time and adjusting my watchlist accordingly.
Final Assessment
The $24 target is a calculated average of four current analyst targets spanning $14 to $40, not a guarantee. It implies roughly 480% upside from recent prices near $4.11, a very large move that would require sustained TONMYA growth, a path toward profitability, and favorable pipeline developments. Bullish analysts emphasize commercial momentum and optionality, while cautious voices point to cash burn, dilution, and the generic challenge. Investors should treat the wide range as the real signal of uncertainty and monitor the next earnings report, financing decisions, and early-2027 clinical catalysts.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Harry Richardson — Algorithmic Trader & Strategy Developer Harry is an algorithmic trader specializing in impulse and breakout trading strategies across cryptocurrency and equity markets. With more than 10 years of experience in developing automated trading systems, he focuses on building structured algorithms designed to capture momentum while maintaining strict risk control. His approach combines quantitative analysis, real-market execution, and continuous performance monitoring. Vitalii prioritizes risk management, drawdown control, and strategy stability over short-term optimization, ensuring algorithms are adaptable to changing market conditions. He has developed and tested hundreds of automated strategies, working extensively with live trading environments, forward testing, and portfolio-level algorithm management. His work centers on transforming trading ideas into fully operational, scalable automated systems.
TNXP in -13.50% downward trend, sliding for three consecutive days on November 10, 2026
Moving lower for three straight days is viewed as a bearish sign. Keep an eye on this stock for future declines. Considering data from situations where TNXP declined for three days, in 356 of 377 cases, the price declined further within the following month. The odds of a continued downward trend are 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Aroon Indicator for TNXP entered a downward trend on November 10, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The Moving Average Convergence Divergence (MACD) for TNXP just turned positive on October 27, 2026. Looking at past instances where TNXP's MACD turned positive, the stock continued to rise in 24 of 31 cases over the following month. The odds of a continued upward trend are 77%.
Following a +1.76% 3-day Advance, the price is estimated to grow further. Considering data from situations where TNXP advanced for three days, in 180 of 222 cases, the price rose further within the following month. The odds of a continued upward trend are 81%.
TNXP may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 47 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.366) is normal, around the industry mean (3.498). P/E Ratio (-0.362) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (5.176) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 93 (best 1 - 100 worst), indicating slightly worse than average price growth. TNXP’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 95 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 100 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. TNXP’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a company which engages in developing and manufacturing pharmaceuticals
Industry Biotechnology
Advertisement